Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6369062 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
US6503911 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
US6617328 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
US6525057 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
US6479496 | MENARINI INTL | Methods for treating angina with ranolazine |
May, 2019
(4 years ago) | |
US6562826 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
US6864258 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
US6852724 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
US6303607 | MENARINI INTL | Method for administering a sustained release ranolanolazine formulation |
May, 2019
(4 years ago) | |
US6620814 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) |
Drugs and Companies using RANOLAZINE ingredient
Market Authorisation Date: 12 February, 2007
Treatment: Treating chronic angina by administering an extended release form of ranolazine
Dosage: TABLET, EXTENDED RELEASE;ORAL